Pegasys + Copegus peginterferon alfa-2a + Copegus (ribavirin)
PEGASYS Medication Guide Pegasys Product Information Copegus Medication Guide Copegus Product Information
Articles on Pegasys + Copegus
Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy 1-12-2010 Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C 1-5-2010 Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression 1-5-2010 HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients 12/04/09 Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy 12/01/09 Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin 11/17/09 Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients 11/17/09 Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12 10-16-2009 Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users 8-14-2009 Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study 7-28-2009 Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin 6-23-2009 Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6 6-19-2009 IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response 5/22/09 Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients 5/08/09 Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy 5/05/09 Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3) 5/05/09 Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity 5/05/09 HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin 4/10/09 Pegylated Interferon alfa-2a (Pegasys) Relapse Rates in Genotype 1 Chronic Hepatitis C Patients Depend on Weight-based Ribavirin Dosage 4/07/09 Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C 4/03/09 Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin 2/27/2009 Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients 2/03/2009 Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response 1/30/2009 Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C 1/27/2009 SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study 12/12/2008 Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders 12/08/2008 Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review 12/082008 Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents 12/02/2008 Nitazoxanide Enhances Anti-HCV Activity of Pegylated interferon/ribavirin and STAT-C Agents 12/02/2008 Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers 11/25/2008 Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin 11/21/2008 Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin 11/18/2008 IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia 11/07/2008 Extended Duration Pegylated Interferon/ribavirin for Prior Non-responders and Relapsers 11/25/2008 IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia 11/07/2008 Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in treatment-naïve patients with chronic hepatitis C genotype 1 infection given as monotherapy and in combination with peginterferon alfa-2a (P) and ribavirin (R) 11/05/2008 Safety and antiviral activity of BI 201335, a new HCV NS3 protease inhibitor, in combination therapy with peginterferon alfa-2a (P) and ribavirin (R) for 28 days in P+R treatment-experienced patients with chronic hepatitis C genotype 1 infection 11/05/2008 Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin 11/05/2008 Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the IDEAL Study 11/05/2008 Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C 10/21/2008 Pegylated Interferon plus Ribavirin Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals 10/17/08 24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response 10/14/08 Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin 10/14/08 Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C 10/10/08 Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma 10/10/08 Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial 9/09/2008 Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin 8/29/2008 Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin 8/19/2008 Body Weight Affects Relapse Rates in Latinos with Genotype 2/3 Hepatitis C Treated with Pegylated Interferon Alfa-2a (Pegasys) plus Ribavirin 8/12/2008 Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) 8/05/2008 Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study 7/22/08 Comparison of the Pegylated Interferons Pegasys and PegIntron for Treatment of Chronic Hepatitis C: Analysis of 16 Randomized Trials 7/18/08 12- Versus 24-week Treatment with Pegylated Interferon plus Ribavirin for Genotype 2 or 3 Chronic Hepatitis C Patients 7/11/08 Studies Explore Lower Doses of Pegylated Interferon and Ribavirin for People with Hepatitis C Virus Genotypes 2 or 3 7/08/08 European Commission Approves Shorter 16-week Course of Pegasys plus Ribavirin for Rapid Responders with HCV Genotypes 2 or 3 and Low Viral Load 7/04/08 Pegylated Interferon Alfa-2a (Pegasys) Continues to Suppress HBV, but Adding Adefovir (Hepsera) Provides No Extra Benefit in PEG for B Trial 6/03/08 Platelet Count Is a Strong Predictor of Sustained Response to Pegylated Interferon/ribavirin in Prior Non-Responders (EPIC 3) 5/20/08 Rapid Virologic Response to Peginterferon alfa and Ribavirin Treatment of Chronic Hepatitis C Predicts Sustained Virologic Response and Relapse 5/20/08 Amino Acid Substitutions in HCV Core Region Predict Poor Response to Pegylated Interferon/ribavirin in Genotype 1b Patients 5/20/08 Pegylated Interferon plus Ribavirin Is Effective for Patients with HCV-HBV Coinfection 5/09/08 Factors Predicting Relapse in Patients with Genotype 2/3 HCV Treated with Pegylated Interferon plus Ribavirin 5/06/08 How Ideal Is the IDEAL Trial?
PegIntron + Rebetol peginterferon alfa-2b + Rebetol (ribavirin)
PEG-INTRON® Prescribing Information REBETOL® Prescribing Information
Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy 1-12-2010 Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C 1-5-2010 Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression 1-5-2010 HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients 12/04/09 Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy 12/01/09 Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin 11/17/09 Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients 11/17/09 Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12 10-13-2009 Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users 8-14-2009 Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study 7-28-2009 Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin 6-23-2009 Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6 6-19-2009 Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients 5-29-2009 IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response 5/22/09 FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C 5/15/09 Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients 5/08/09 Pegylated Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal Varices in Hepatitis C Patients with Cirrhosis 5/05/09 Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients 5/05/09 Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy 5/05/09 Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3) 5/05/09 Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity 5/05/09 Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial) Final Analysis 5/05/09 Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study) 5/05/09 Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C 5/05/09 HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin 4/10/09 Review Finds Albumin Interferon for Chronic Hepatitis C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated Interferon 3/20/2009 FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment 3/13/2009 FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment 3/13/2009 Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin 2/27/2009 Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients 2/03/2009 Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response 1/30/2009 Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C 1/27/2009 PegIntron plus Ribavirin Approved for Children with Chronic Hepatitis C 1/05/2009 SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study 12/12/2008 Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders 12/08/2008 Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review 12/082008 Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin 11/21/2008 Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin 11/18/2008 IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia 11/07/2008 Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study 11/05/2008 Probability of Sustained Virologic Response (SVR) Is Associated With the Magnitude of HCV RNA Reduction at Week 4 of Treatment With Peginterferon (PEG) Plus Ribavirin (RBV): Results of the IDEAL Trial 11/05/2008 Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin 11/05/2008 Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the 11/05/2008 Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C 10/21/2008 Pegylated Interferon plus Ribavirin Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals 10/17/08 24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response 10/14/08 Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin 10/14/08 Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C 10/10/08 Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma 10/10/08 Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial 9/09/2008 Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin 8/29/2008 Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin 8/19/2008 Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin 8/19/2008 Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) 8/05/2008 Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study 7/22/08 How Ideal Is the IDEAL Trial?
Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy 1-12-2010 Management of Non-responders and Relapsers Treated with Pegylated Interferon plus Ribavirin for Chronic Hepatitis C 1-5-2010 Low-dose Pegylated Interferon Maintenance Therapy Does Not Reduce Clinical Outcomes despite Persistent HCV Suppression 1-5-2010 HCV Viral Load Decline during First 48 Hours of Pegylated Interferon plus Ribavirin in HCV Monoinfected and HCV/HIV Coinfected Patients 12/04/09 Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy 12/01/09
Genotype 1 Chronic Hepatitis C Patients with Low Viral Load Can Achieve Sustained Response with 24 Weeks of Pegylated Interferon plus Ribavirin 11/17/09 Pegylated Interferon plus Ribavirin Can Effectively Treat both Hepatitis B and C In Dually Infected Patients 11/17/09 Reducing Ribavirin Dose Raises Relapse Risk for Chronic Hepatitis C Patients, but Pegylated Interferon May be Decreased after Week 12 10-13-2009 Advocates Urge Consideration of Hepatitis C Treatment for Active Injection Drug Users 8-14-2009 Pegasys and PegIntron for Chronic Hepatitis C Perform Similarly in IDEAL Study 7-28-2009 Detectable HCV RNA at Week 8 Is Best Predictor of Relapse in Genotype 1 Hepatitis C Patients Treated with Pegylated Interferon plus Ribavirin 6-23-2009 Effectiveness of Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Patients with HCV Genotypes 5 or 6 6-19-2009 Reduced Dose and Duration of PegIntron plus Ribavirin Is Not as Effective as Standard Therapy for Genotype 2 and 3 Hepatitis C Patients 5-29-2009 IDEAL Study Shows that Greater Hemoglobin Decline during Treatment with Pegylated Interferon plus Ribavirin Is Associated with Better Response 5/22/09 FDA Approves Dose Adjustments of PegIntron and Rebetol for Certain Patients with Chronic Hepatitis C 5/15/09 Extended 72-week Treatment with Pegylated Interferon plus Ribavirin Did Not Improve Outcomes among Slow Responder Hepatitis C Patients 5/08/09 Pegylated Interferon alfa-2b (PegIntron) Maintenance Monotherapy May Reduce Esophageal Varices in Hepatitis C Patients with Cirrhosis 5/05/09 Adding Boceprevir to PegIntron/Ribavirin Significantly Improves Sustained Virological Response in Chronic Hepatitis C Patients 5/05/09 Early Treatment of Acute Hepatitis C with Pegylated Interferon Monotherapy Produces Better Results than Delayed Combination Therapy 5/05/09 Adding Telaprevir Improves Sustained Response to Pegylated Interferon plus Ribavirin in Genotype 1 Chronic Hepatitis C Patients (PROVE3) 5/05/09 Experimental HCV Protease Inhibitor SCH 900518, with or without Pegylated Interferon, Appears Safe and Exhibits Good Antiviral Activity 5/05/09 Reduced Dose and Duration of Peginterferon alfa-2b and Weight-Based Ribavirin in European and Asian Genotype 2 and 3 Chronic Hepatitis C Patients (REDD 2/3 Trial) Final Analysis 5/05/09 Individualized treatment duration with peginterferon alfa-2b and ribavirin for 24, 30 or 36 weeks in HCV genotype 1-infected patients with undetectable HCV-RNA early during therapy (INDIV-2 study) 5/05/09 Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C 5/05/09 HIV Positive and Negative Individuals with Acute or Early Chronic Hepatitis C Respond Well to 24 Weeks of Pegylated Interferon plus Ribavirin 4/10/09 Review Finds Albumin Interferon for Chronic Hepatitis C Is Effective and Well-tolerated; Phase 3 Results Show Non-inferiority to Pegylated Interferon 3/20/2009 FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment 3/13/2009 FDA Approves New Indication for PegIntron plus Ribavirin for Certain Patients Who Failed Prior Hepatitis C Treatment 3/13/2009 Phase 1 OPTIMA Trial Finds Controlled-release Nitazoxanide Improves Response to Pegylated Interferon plus Ribavirin 2/27/2009 Extended Pegylated Interferon plus Ribavirin Therapy Improves Sustained Response Rate in Slow Responder Genotype 1b Hepatitis C Patients 2/03/2009 Adherence to Pegylated Interferon/ribavirin Therapy for Hepatitis C and Early Treatment Response 1/30/2009 Combination of Virus and Host Factors Predict Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C 1/27/2009 PegIntron plus Ribavirin Approved for Children with Chronic Hepatitis C 1/05/2009 SAMe Improves Early Response to Pegylated Interferon/ribavirin in Small Study 12/12/2008 Long-term Low-dose Pegylated Interferon May Improve Liver Inflammation and Fibrosis in a Select Subgroup of Prior Non-responders 12/08/2008 Results of the IDEAL Study of Treatment of African Americans with Chronic Hepatitis C: A Slide Set Review 12/082008 Canadian POWeR Study Finds Patients with Advanced Liver Disease Respond Poorly to Pegylated Interferon plus Ribavirin 11/21/2008 Genotype 1 HCV Patients with Early but Not Rapid Response May Benefit from 72 Weeks of Pegylated Interferon plus Ribavirin 11/18/2008 IDEAL Researchers Look at Predictors of Response to Pegylated Interferon plus Ribavirin, including Race/ethnicity and Anemia 11/07/2008 Boceprevir Plus Peginterferon alfa-2b/Ribavirin for Treatment of Genotype 1 Chronic Hepatitis C in Previously Untreated Patients: Interim Results from the HCV SPRINT-1 Study 11/05/2008 Probability of Sustained Virologic Response (SVR) Is Associated With the Magnitude of HCV RNA Reduction at Week 4 of Treatment With Peginterferon (PEG) Plus Ribavirin (RBV): Results of the IDEAL Trial 11/05/2008 Hematologic Safety Data From the IDEAL Trial: Neutropenia, Anemia, and Thrombocytopenia Profiles of Peginterferon alfa/Ribavirin 11/05/2008 Treatment-Related Anemia Is Associated With Higher SVR Rates Among Persons Treated With Peginterferon (PEG)/Ribavirin (RBV): Results From the 11/05/2008 Response to Pegylated Interferon plus Ribavirin in Asian Patients with Genotype 1 Chronic Hepatitis C 10/21/2008 Pegylated Interferon plus Ribavirin Produces High Sustained Response Rate in HBV-HCV Coinfected Individuals 10/17/08 24 Weeks of Pegylated Interferon plus Ribavirin May Be Sufficient for Selected Genotype 1/4 Chronic Hepatitis C Patients with Rapid Response 10/14/08 Individuals with HCV Genotype 6 Respond Well to Pegylated Interferon plus Ribavirin 10/14/08 Higher Doses of Pegylated Interferon and Ribavirin May Increase Sustained Response Rates in Hard-to-Treat Patients with Chronic Hepatitis C 10/10/08 Sustained Virological Response to Pegylated Interferon plus Ribavirin for Chronic Hepatitis C Does Not Always Prevent Hepatocellular Carcinoma 10/10/08 Genetic Variation Linked to Sustained Response to Pegylated Interferon plus Ribavirin in HALT-C Trial 9/09/2008 Insulin-sensitizing Agent Pioglitazone (Actos) Did Not Improve Response to Re-treatment with Pegylated Interferon plus Ribavirin 8/29/2008 Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin 8/19/2008 Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin 8/19/2008 Eight Weeks of Pegylated Interferon plus Ribavirin for Genotype 2 Chronic HCV Patients with Rapid Virological Response (RVR) 8/05/2008 Telaprevir plus Pegylated Interferon and Ribavirin Produces Rapid Response and Is Well Tolerated in 28-day Study 7/22/08 How Ideal Is the IDEAL Trial?
Intron A + Rebetol (interferon alfa-2b + ribavirin)
Articles on Intron A + Rebetol
Management of Depression During Hepatitis C Treatment with Interferon-based Therapy 1/29/2010 Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy 1/12/2010 Sustained Response to Interferon-based Therapy Leads to Improved Quality of Life in Chronic Hepatitis C Patients 12/11/09 Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy 12/01/09 Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients 11/24/09 HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients 9-18-2009 FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues 9-04-2009 Genetic Variation Helps Explain Differences in Response to Interferon-based Therapy for Hepatitis C 8-21-2009 Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse 7-17-2009 Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients 7-07-2009 Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C 7-07-2009 Older Genotype 3 Chronic Hepatitis C Patients Do Not Respond as Well to Interferon-based Therapy 6-16-2009 Vitamin B12 Levels May Help Predict Response to Interferon-based Therapy for Chronic Hepatitis C 6-5-2009 HCV Viral Load Decline at Day 2 of Interferon-based Therapy Predicts Sustained Response, Explains Poorer Outcomes in African-Americans 6-2-2009 Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response 4/21/09 Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients 4/21/09 A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy 4/13/09 Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C 4/03/09 Cyclical Treatment Interruption in Patients Taking Interferon-based Therapy for Chronic Hepatitis C 2/10/2009 CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C 12/05/2008 Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients 11/21/2008 Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C 11/14/2008 Sustained Response to Interferon-based Therapy Reduces the Likelihood of Type 2 Diabetes 6/24/08 Selected Hepatitis C Patients with Decompensated Cirrhosis Can Benefit from Interferon-based Therapy prior to Liver Transplantation 6/10/08 Response to Controlled-release Interferon Alfa-2b (Locteron) in Genotype 1 Hepatitis C Patients 5/23/08 Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C 5/20/08 Clearance of HCV in Children at 5-Year Follow-up Is Predicted by Sustained Virologic Response at 24 Weeks Post Treatment With Interferon alfa-2b Plus Ribavirin 5/20/08 Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C 5/20/08 Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin Non-Responders (NR) 5/20/08 Response to Interferon-based Therapy in Hispanic Patients with Chronic Hepatitis C 5/20/08 Rapid Virological Response Is a Stronger Predictor than HCV Genotype of Sustained Response to Interferon-based Therapy 5/13/08
Roferon A + Ribavirin (interferon alfa-2a + ribavirin)
Management of Depression During Hepatitis C Treatment with Interferon-based Therapy 1/29/2010 Influence of HCV Subtype and Quasispecies on Virological Response to Interferon-Based Therapy 1/12/2010 Hepatitis C Treatment Appears to Be Declining; People with Hard-to Treat Genotypes Are Half as Likely to Receive Therapy 12/01/09 Sustained Virological Response to Interferon-based Therapy Slows Progression of Liver Cirrhosis in Hepatitis C Patients 11/24/09 HCV Viral Load Decline during the First 24 Hours of Interferon-based Therapy Predicts Long-term Outcomes in HIV-HCV Coinfected Patients 9-18-2009 FDA Requires Updated Labeling for Interferon Alpha Products Due to Recently Identified Safety Issues 9-04-2009 Increases in ALT Late in the Course of Interferon-based Therapy for Chronic Hepatitis C Predicts Relapse 7-17-2009 Interferon-based Therapy Reduces or Reverses Liver Fibrosis over the Long-term in Chronic Hepatitis C Patients 7-07-2009 Early Bilirubin Elevation May Predict Severe Anemia during Interferon/ribavirin Treatment for Chronic Hepatitis C 7-07-2009 Interferon-based Therapy for Hepatitis C Improves Fibrosis Even in Individuals without Virological Response 4/21/09 Sustained Response to Interferon-based Therapy Reduces Risk of Diabetes in Hepatitis C Patients 4/21/09 A Small Proportion of Hepatitis C Patients Develop Liver Cancer despite Sustained Response to Interferon-based Therapy 4/13/09 Overview of the Current Standard of Care for Treatment of Chronic Hepatitis C 4/03/09 CD4 T-cell Responses to HCV during and after Interferon-based Therapy for Chronic Hepatitis C 12/05/2008 Therapies to Manage Insulin Resistance Improve Response to Interferon-based Therapy in Chronic Hepatitis C Patients 11/21/2008 Sexual Desire, Function, and Satisfaction in Men Undergoing Treatment with Interferon-based Therapy for Chronic Hepatitis C 11/14/2008 Significance of Transient HCV Viral Load "Blips" during Interferon-based Therapy for Chronic Hepatitis C 5/20/08 Symptoms and Response to Interferon plus Ribavirin in Children with Chronic Hepatitis C 5/20/08 Results from the EPIC3 Program: Platelet Counts Are Strong Predictors of Sustained Viral Response (SVR) in the Re-Treatment of Previous Interferon/Ribavirin Non-Responders (NR) 5/20/08 HCV Genotypes 2 and 3 Do Not Respond the Same to Interferon-based Treatment 1/29/08 Interferon-based Therapy Lowers Lymphoma Risk in Hepatitis C Patients 1/25/08
Cirrhosis Fibrosis Hepatocellular Carcinoma Liver Transplantation Liver Biopsy Steatosis Anemia Children / Infants / Women Drug Abuse Experimental Treatments FAQs About Hepatitis C Genotypes Insulin Resistance / Diabetes Sustained Viral Response (SVR) Tests for HCV Vaccines for HCV
